Karyopharm Therapeutics Inc. (NASDAQ: KPTI): Surviving A Volatility – Stocks Register
Home  »  Business   »  Karyopharm Therapeutics Inc. (NASDAQ: KPTI): Survi...

Karyopharm Therapeutics Inc. (NASDAQ: KPTI): Surviving A Volatility

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) price closed higher on Monday, September 13, jumping 3.45% above its previous close.

>> 7 Top Picks for the Post-Pandemic Economy <<

A look at the daily price movement shows that the last close reads $5.79, with intraday deals fluctuated between $5.685 and $6.135. The company’s 5Y monthly beta was ticking 0.20. Taking into account the 52-week price action we note that the stock hit a 52-week high of $18.00 and 52-week low of $4.42. The stock added 24.27% on its value in the past month.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored


Karyopharm Therapeutics Inc., which has a market valuation of $448.35 million, is expected to release its quarterly earnings report Nov 01, 2021 – Nov 05, 2021. Analysts tracking KPTI have forecast the quarterly EPS to shrink by -0.67 per share this quarter, while the same analysts predict the annual EPS to hit -$2.82 for the year 2021 and up to -$1.96 for 2022. In this case, analysts estimate an annual EPS growth of -3.70% for the year and 30.50% for the next year.

On average, analysts have forecast the company’s revenue for the quarter will hit $25.8 million, with the likely lows of $21.1 million and highs of $33.06 million. The average estimate suggests sales growth for the quarter will likely rise by 20.90% when compared to those recorded in the same quarter in the last financial year. Staying with the analyst view, there is a consensus estimate of $97.8 million for the company’s annual revenue in 2021. Per this projection, the revenue is forecast to grow -9.50% below that which the company brought in 2021.

Revisions to the company’s EPS highlights a short term direction of a stock’s price movement, which in the last 7 days came up with no upward and no downward reviews. On the technical perspective front, indicators give KPTI a short term outlook of 50% Sell on average. Looking at the stock’s medium term indicators we note that it is averaging as a 100% Sell, while an average of long term indicators are currently assigning the stock as 100% Sell.

Here is a look at the average analyst rating for the stock as represented on a scale of 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock is strong buy or strong sell respectively. Specifically, 10 analysts have assigned KPTI a recommendation rating as follows: 3 rate it as a Hold; 4 advise Buy while 2 analyst(s) assign an Overweight rating. 0 analyst(s) have tagged the Karyopharm Therapeutics Inc. (KPTI) stock as Underweight, with 1 recommending Sell. In general, analysts have rated the stock Overweight, a scenario likely to bolster investors out for an opportunity to add to their holdings of the company’s shares.

The overview shows that KPTI’s price is at present 13.20% off the SMA20 and -16.46% from the SMA50. The Relative Strength Index (RSI) metric on the 14-day timeframe is pointing at 50.37, with weekly volatility standing at 6.18%. The indicator jumps to 6.65% when calculated based on the past 30 days. Karyopharm Therapeutics Inc. (NASDAQ:KPTI)’s beta value is holding at 0.20, while the average true range (ATR) indicator is currently reading 0.39. Considering analysts have assigned the stock a price target range of $6.00-$29.00 as the low and high respectively, we find the trailing 12-month average consensus price target to be $15.22. Based on this estimate, we see that current price is roughly -0.17% off the estimated low and -384.14% off the forecast high. Investors will no doubt be excited to see the share price fall to $15.00, which is the median consensus price, and at that level KPTI would be -150.42% from current price.

Turning out attention to how the Karyopharm Therapeutics Inc. stock has performed in comparison to its peers in the industry, here’s what we find: KPTI’s stock is 3.45% on the day and -57.82% in the past 12 months, while Bristol-Myers Squibb Company (BMY) traded -0.46% in the last session and was positioned 6.53% up on its price 12 months ago. Another comparison is with Abbott Laboratories (ABT) whose stock price was down -1.69% in the last trading session, and has flourished 20.94% over the past year. Also, Exelixis Inc. (EXEL) showed up trend of 1.30% while its price kept floating at -6.95% over the past year. Elsewhere in the market, the S&P 500 Index has rallied 0.23% in last trading session, with the Dow Jones Industrial also saw a positive session on the day with 0.76%.

An analysis of the Karyopharm Therapeutics Inc. (NASDAQ:KPTI) stock in terms of its daily trading volume indicates that the 3-month average is 1.49 million.

>> 7 Top Picks for the Post-Pandemic Economy <<

Current records show that the company has 75.19M in outstanding shares. The insiders’ percentage holdings are 2.90% of outstanding shares while the percentage share held by institutions stands at 80.50%. But the -61.30% downside, the stock’s price has registered year-to-date as of last trading, will likely reignite investor interest given the prospect of it rallying even higher.

Leave a Comment

Your email address will not be published. Required fields are marked *

Related Posts

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam